Atara Biotherapeutics Inc (NASDAQ:ATRA) EVP Heather D. Turner sold 12,214 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $38.01, for a total transaction of $464,254.14. Following the sale, the executive vice president now owns 77,112 shares in the company, valued at approximately $2,931,027.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Atara Biotherapeutics Inc (NASDAQ:ATRA) traded down $2.23 on Monday, hitting $39.48. 1,388,248 shares of the stock were exchanged, compared to its average volume of 1,370,000. The stock has a market capitalization of $1,210.00, a price-to-earnings ratio of -11.38 and a beta of 2.71. Atara Biotherapeutics Inc has a 12 month low of $11.80 and a 12 month high of $44.00.

A number of analysts have recently issued reports on ATRA shares. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price objective on the stock in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. ValuEngine upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Cowen started coverage on shares of Atara Biotherapeutics in a research note on Friday, January 26th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $30.60.

Several large investors have recently modified their holdings of ATRA. SG Americas Securities LLC bought a new stake in shares of Atara Biotherapeutics in the third quarter worth $142,000. Voya Investment Management LLC increased its stake in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,651 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Atara Biotherapeutics in the third quarter worth $170,000. The Manufacturers Life Insurance Company increased its stake in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after buying an additional 1,369 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after buying an additional 610 shares during the last quarter. Institutional investors and hedge funds own 69.58% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Atara Biotherapeutics Inc (ATRA) EVP Sells 12,214 Shares of Stock” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/12/insider-selling-atara-biotherapeutics-inc-atra-evp-sells-12214-shares-of-stock.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.